8 results about "Immunocompromised patient" patented technology

A method for treating an immunocompromised patient including collecting from patient values for at least one variable selected from the group, inputting the values for the one or more variables to a neural network (NN) performed on one or more computers to produce a score indicative of likelihood of response or non-response to an anti-viral drug and a score indicative of likelihood of response or non-response to Virus-Specific T-Cells (VSTs) and administering an antiviral drug to a patient who has a threshold score indicative of a likelihood of a response to anti-viral therapy and administering VSTs to a patient who has a threshold score indicative of a likelihood of a response to VST therapy.

The present disclosure provides methods for treating or inhibiting the growth of a tumor, including selecting a patient with cancer, wherein the patient is immunosuppressed or immunocompromised, and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody, such as cemiplimab or a bioequivalent thereof). In certain embodiments, the cancer is skin cancer, such as cutaneous squamous cell carcinoma.

The present invention discloses an indole styryl oxadiazole bridged compound having anti-Toxoplasma activity, comprising a compound formed by bridging three pharmacophores: 3-indoleacetonitrile, oxadiazole, and cinnamic acid. The present invention relates to the field of antiparasitic technology and has the beneficial effects of providing a new chemical entity for the development of anti-Toxoplasma drugs and opening up new directions for the design of antiparasitic drugs. The compound has broad application prospects, particularly in the treatment of immunocompromised patients and the prevention and control of Toxoplasma gondii in the livestock and aquaculture industry.

Virus-Like Particles derived from the subfamilies, Parahepevirinae, which infect trout and salmon, and the Orthohepevirinae, which infect mammals and birds, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are also disclosed. Major aspects of the invention relate to compositions of Virus-Like Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus-Like Particles. Preferred aspects relate to functional capsids comprising polypeptide sequences comprising one or more amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, wherein said variant polypeptides are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV). Other aspects include the design and assembly of modified vectors to facilitate the basic and applied studies leading to the development and commercialization of novel drug products, and as tools advancing the interests of institutions involved in animal and human healthcare.

A method of reducing or treating parainfluenza or influenza virus infection in an immunocompromised patient by administering to the respiratory tract of the patient a composition comprising a therapeutically effective amount of protein having sialidase activity.

Virus-Like Particles derived from the subfamilies, Parahepevirinae and Orthohepevirinae, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are disclosed. Compositions of VirusLike Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus- Like Particles are provided. Functional capsids comprising polypeptide sequences comprising amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, that are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV) are provided.

A method of prophylactic management of an immunocompromised patient with a mask having a fan assembly is provided. The method includes the mask being fitted to a face and covering a nose and mouth of the patient. The mask is secured to a head of the patient with a set of fasteners. The fan assembly is activated with a power supply to exhaust air from the mask at a rate of at least 5 liters per minute of air flow and dispel particulate matter to inhibit pathogens being inhaled by the patient.

A method of prophylactic management of an immunocompromised patient with a mask having a fan assembly is provided. The method includes the mask being fitted to a face and covering a nose and mouth of the patient. The mask is secured to a head of the patient with a set of fasteners. The fan assembly is activated with a power supply to exhaust air from the mask at a rate of at least 5 liters per minute of air flow and dispel particulate matter to inhibit pathogens being inhaled by the patient.